1320336-58-0

Basic information

• Product Name: (1R,2R,3S,4S,5R,6R)-2,3,4-tris(benzyloxy)-5-((benzyloxy)methyl )-7-oxabicyclo[4.1.0]heptane
• Synonyms: (1R,2R,3S,4S,5R,6R)-2,3,4-tris(benzyloxy)-5-((benzyloxy)methyl )-7-oxabicyclo[4.1.0]heptane
• CAS NO: 1320336-58-0
• Molecular Weight: 536.668
• Mol File: 1320336-58-0.mol
• Article Data: 4

Chemical Properties

• CAS DataBase Reference: (1R,2R,3S,4S,5R,6R)-2,3,4-tris(benzyloxy)-5-((benzyloxy)methyl )-7-oxabicyclo[4.1.0]heptane(CAS DataBase Reference)
• NIST Chemistry Reference: (1R,2R,3S,4S,5R,6R)-2,3,4-tris(benzyloxy)-5-((benzyloxy)methyl )-7-oxabicyclo[4.1.0]heptane(1320336-58-0)
• EPA Substance Registry System: (1R,2R,3S,4S,5R,6R)-2,3,4-tris(benzyloxy)-5-((benzyloxy)methyl )-7-oxabicyclo[4.1.0]heptane(1320336-58-0)

Safety Data

• Hazardous Substances Data: 1320336-58-0(Hazardous Substances Data)

Upstream product

• 1319731-21-9 (3S,4S,5S,6R)-6-(hydroxymethyl)-3,4-dibenzyloxy-5-hydroxycyclohex-1-ene 
• 100-39-0 benzyl bromide 
• 1319731-18-4 (3S,4R,5S,6R)-6-(benzyloxymethyl)-3,4,5-(tribenzyloxy)cyclohex-1-ene 

Downstream Products

• 924298-42-0 (1R,2S,3S,4S,5R)-2,3,4-tris(benzyloxy)-5-(benzyloxymethyl)cyclohexanol 
• 1319731-23-1 (1S,2R,3S,4R,5S)-3,4,5-tris(benzyloxy)-2-(benzyloxymethyl)cyclohexanol 
• 1319731-24-2 (1S,2S,3S,4S,6R)-4-azido-6-benzyloxymethyl-1,2,3-tris(benzyloxy)cyclohexane 
• 1319731-29-7 (1R,2S,3S,4S,5S,6S)-2-azido-3,4,5-tris(benzyloxy)-6-((benzyloxy)methyl)cyclohexan-1-ol 
• 1319731-28-6 (1R,2S,3R,4S,5S,6S)-2-azido-4,5,6-tris(benzyloxy)-3-((benzyloxy)methyl)cyclohexan-1-ol 
• 1319731-11-7 (1S,2S,3S,4S,5R)-2,3,4-tris(benzyloxy)-5-(benzyloxymethyl)cyclohexanamine 
• 1319731-12-8 (1R,2S,3S,4S,5S,6S)-2-amino-3,4,5-tris(benzyloxy)-6-(benzyloxymethyl)cyclohexanol 
• 1319731-13-9 N-((S)-1-((4S,5R)-2,2-dimethyl-5-tetradecyl-1,3-dioxolan-4-yl)-2-((1S,2S,3S,4S,5R)-2,3,4-tris(benzyloxy)-5-(benzyloxymethyl)cyclohexylamino)ethyl)-2-nitrobenzenesulfonamide 
• 1319731-14-0 N-((S)-1-((4S,5R)-2,2-dimethyl-5-tetradecyl-1,3-dioxolan-4-yl)-2-((1S,2S,3S,4S,5S,6R)-2,3,4-tris(benzyloxy)-5-(benzyloxymethyl)-6-hydroxycyclohexylamino)ethyl)-2-nitrobenzenesulfonamide 
• 1319731-15-1 (S)-1-((4S,5R)-2,2-dimethyl-5-tetradecyl-1,3-dioxolan-4-yl)-N-((1S,2S,3S,4S,5R)-2,3,4-tris(benzyloxy)-5-(benzyloxymethyl)cyclohexyl)ethane-1,2-diamine 
• 1319731-16-2 (1R,2S,3S,4S,5S,6S)-2-((S)-2-amino-2-((4S,5R)-2,2-dimethyl-5-tetradecyl-1,3-dioxolan-4-yl)ethylamino)-3,4,5-tris(benzyloxy)-6-(benzyloxymethyl)cyclohexanol 
• 1319731-17-3 N-((S)-1-((4S,5R)-2,2-dimethyl-5-tetradecyl-1,3-dioxolan-4-yl)-2-((1S,2S,3S,4S,5R)-2,3,4-tris(benzyloxy)-5-(benzyloxymethyl)cyclohexylamino)ethyl)cerotamide 
• 1319731-41-3 N-((S)-1-((4S,5R)-2,2-dimethyl-5-tetradecyl-1,3-dioxolan-4-yl)-2-((1S,2S,3S,4S,5S,6R)-2,3,4-tris(benzyloxy)-5-(benzyloxymethyl)-6-hydroxycyclohexylamino)ethyl)cerotamide 
• 1319731-09-3 N-((S)-1-((1S,2R)-1,2-dihydroxyhexadecyl)-2-((1S,2S,3S,4S,5R)-2,3,4-trihydroxy-5-hydroxymethylcyclohexylamino)ethyl)cerotamide hydrochloride 

Relevant articles and documents

PHARMACOLOGICAL CHAPERONES FOR ENZYME TREATMENT THERAPY

The present invention relates to therapeutic methods for the management of a patient's lysosomal storage disease by enzyme replacement therapy. The methods involve the use of combinations of, and kits containing: a) an exogenous lysosomal hydrolaseor an e

Potent and selective activity-based probes for GH27 human retaining α-galactosidases

Lysosomal degradation of glycosphingolipids is mediated by the consecutive action of several glycosidases. Malfunctioning of one of these hydrolases can lead to a lysosomal storage disorder such as Fabry disease, which is caused by a deficiency in α-galac